Go to the list of all blogs
Allana's Avatar
published in Blogs
Dec 26, 2022
TickeronGET DAILY SIGNALS

Top Biotech Stocks Next Week Trading Opportunities (PRVB, SRPT, ALNY, VIR, BCRX)

Signals from Pattern Search Engine

Tickeron is bringing high-powered Artificial Intelligence (A.I.) technology to the retail investment community that, in our opinion, rivals the technology and approach used at major Wall Street firms. The Ph. D founders of Tickeron have spent several years researching and building an Artificial Intelligence-based search engine that allows active investors to perform thousands of hours of research and pattern searches...in just minutes.

A security pattern traces distinct movements of security prices that, once recognized, helps investors make informed trading decisions. Patterns are identified by their key geometrical elements, formed by changing security prices.

Every day Artificial Intelligence analyses 39 patterns for 8000 stocks, 3000 ETFs, most popular Crypto & Forex pairs and presents trading ideas with backtest and statistic results.

BUY signal for PRVB (Broadening Wedge Ascending)

The Broadening Wedge Ascending pattern forms when the price of a security progressively makes higher highs (1, 3) and higher lows (2, 4), following two widening trend lines. This pattern may form when large investors spread their buying over a period of time.

 

The theory goes that after initial buying occurs, other market participants react to the rising price and jump on the bandwagon to participate. Then value investors begin to sell, believing the price has risen too much, which spurs the original large investor to resume buying again.

Trade Idea:

BUY near the Breakout (Entry) price – $9.95

SELL at the Target (Exit) price – $11.08

Subscribe and get 14-days free trial

 

Signals from Trend Prediction Engine

Trend trading is a strategy based on the technical analysis of changing market prices. The trend trader enters into a long position when a stock is trending upward and uses the short position when a stock is trending downward.

Tickeron's End-of-Day Trend Prediction Engine will instantly generate AI-driven projections on whether a stock is going up or down for the next week or month. The algorithm looks at past price changes and generates unique insights into future fluctuations. TPE analyzes trends for stocks, penny stocks, ETFs, mutual funds, cryptocurrencies, and Forex. To make this tool more convenient, it’s best to customize it by adjusting the confidence level, price range, asset classes, and many others. You can also set up notifications for emails or push notifications.

  BUY signals for SRPT, ALNY, VIR

Trade Idea:

BUY  at the opening of the Stock Market on Monday if the opening price has gone up by no more than 0.5% of the closing price of Friday.

SELL after the price has risen by 2% from the closing price on Friday, or at the end of the trading week if the target is not reached.

Subscribe and get a 14-days free trial

 

Signals from Buy/Sell Analytical System

Buy/Sell recommendations is a complex analytical system consisting of several blocks:

TA score - signals from several technical indicators (MACD, RSI, Stochastic, etc.) are processed using neural networks.

FA score - complex fundamental analysis based on quantitative comparative ratings (Valuation, P/E Growth, SMR etc.)

Buy / Sell rating system - processes the aggregate score results and generates a trading signal.

BUY signal for BCRX

Trade idea:

Step 1. BUY BCRX at the current market price.

Step 2. Set up alerts for BCRX from Buy/Sell Analytical System.

Step 3. SELL BCRX after receiving the "SELL" recommendation.

Subscribe to our BUY/SELL recommendations for 8000 stocks, 9000 OTC stocks, 3000 ETFs and 25000 Mutual Funds only for 39$ per year.

 

Related Ticker: VIR

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


VIR in upward trend: price rose above 50-day moving average on October 26, 2026

VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.

The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +8.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 128 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 51 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.895) is normal, around the industry mean (3.104). P/E Ratio (-6.215) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 58 to 140.2B. VRTX holds the highest valuation in this group at 140.2B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was -20%. INO experienced the highest price growth at 117%, while ABOS experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 53% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
VIR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases

Industry Biotechnology

Industry
N/A
Address
1800 Owens Street
Phone
+1 415 906-4324
Employees
367
Web
https://www.vir.bio
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.
Consensus estimates call for Q3 FY2026 revenue of approximately $3.37 billion, in line with the company's guidance midpoint of $3.35 billion. Non-GAAP earnings per share (EPS) expected at $9.16, edging above the guided midpoint of $9.08.